AAV Genome Sequencing Service Market Is Booming Rapidly with Strong Demand By 2033 | Thermo Fisher Scientific, Illumina, Danaher Corporation
Coherent Market Insights has published a new research study on the Global "AAV Genome Sequencing Service Market" forecasting growth through 2033. The report segments the market by type, application, end-user, and region, identifying key players like Thermo Fisher Scientific, Illumina, and Danaher Corporation. It aims to provide a comprehensive analysis of market trends, drivers, restraints, competitive landscape, and regional dynamics to aid strategic decision-making.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock rally by 2.73% to $126.63 on Wednesday, outperforming the broader market. This marked the third consecutive day of gains for Illumina, as the S&P 500 Index and Dow Jones Industrial Average also rose. The article highlights Illumina's strong performance relative to its competitors on a positive trading day.
Illumina Inc (ILMN) Stock Price Quote Today & Current Price Chart
This article provides the current stock price quote and chart for Illumina Inc (ILMN). It indicates that the content is related to online trading via the Capital.com smart investment app.
Illumina Inc. stock underperforms Friday when compared to competitors
Illumina Inc. (ILMN) stock underperformed on Friday, falling 5.41% to $117.67. This occurred during a broad market downturn, with the S&P 500 Index and Dow Jones Industrial Average also experiencing significant losses. This marks the second consecutive day of losses for Illumina's stock.
Assessing Illumina (ILMN) Valuation After New Labcorp And Preventive Genomics Alliances
Illumina has recently expanded its collaborations with Labcorp and entered a new consortium, driving its stock momentum, with a 5.2% 30-day return. Despite recent gains, the 1-year return is strong, contrasting with weaker 3 and 5-year returns, indicating a recent upturn. The company is currently valued at a discount to analyst targets and an intrinsic value estimate of $136.05, raising questions about whether current pricing fully accounts for future growth from these new alliances.
Illumina Inc. stock faces headwinds amid Grail divestiture scrutiny and biotech sector slowdown
Illumina Inc. is facing significant challenges, including regulatory scrutiny over its past Grail acquisition and a slowdown in the biotech sector. Despite a robust balance sheet and ongoing R&D investments, the company's stock is under pressure from softening demand in genomic sequencing, increased competition, and lingering legal ramifications from the Grail divestiture. Investors are closely watching if Illumina can successfully navigate these headwinds and recover its growth trajectory.
Illumina price gives in to negative pressure - Forecast today - 24-03-2026
Illumina's (ILMN) stock price experienced a decline due to a short-term corrective bearish wave and negative pressure from its 50-day SMA, coupled with overbought Stochastic indicators. Analysts predict further decline, targeting a key support level at $115.30 unless it breaks above $128.15. The article also provides bearish forecasts for Alibaba and Snap, and a bullish forecast for Western Digital.
US Multiomic Market Set to Boom Rapidly, Witnessing Strong
Coherent Market Insights has released a new research study on the Global "US Multiomic Market" forecasting strong growth through 2033. The report segments the market by type (Genomics, Proteomics, Metabolomics) and applications (Precision Medicine, Drug Discovery, Clinical Research), and provides competitive and regional analysis. Key players include Illumina Inc., Thermo Fisher Scientific Inc., and Agilent Technologies Inc.
TruPath™ Genome enables deeper insight into complex genomic regions
This article introduces Illumina's TruPath™ Genome, a new tool designed to offer deeper insights into complex genomic regions. Steve Barnard explains how this approach addresses research challenges and enables comprehensive genome interpretation without needing changes to existing sequencing infrastructure. The technology aims to advance genomic research by providing more detailed data.
Nordea Investment Management AB Has $124.15 Million Stake in Illumina, Inc. $ILMN
Nordea Investment Management AB significantly increased its stake in Illumina, Inc. by 2,792.2% in Q4, acquiring 911,843 additional shares to hold a total of 944,500 shares valued at approximately $124.15 million. This move comes as Illumina reported Q4 earnings that beat estimates, with EPS of $1.35 and revenue of $1.16 billion, and issued promising FY2026 guidance. Analyst sentiment for Illumina is mixed, with an average "Hold" rating and an average price target of $129.69, despite some firms raising their targets to around $170.
Here’s Why Illumina Could Continue Its 47% Last Year Rally
Illumina's stock rally is supported by strong Q4 2025 earnings, particularly 20% clinical consumables growth outside China, and strategic partnerships. The company projects significant revenue and EPS growth for 2026, driven by its NovaSeq X platform and recent SomaLogic acquisition. While analysts have a mixed view, TIKR's valuation model suggests a higher price target, emphasizing the operational re-rating and margin expansion potential.
Illumina and Labcorp Expand Precision Oncology Testing Partnership
Illumina and Labcorp have expanded their collaboration to advance precision oncology through next-generation sequencing (NGS) by developing distributed IVD test offerings and co-commercializing liquid and tissue biopsy assays. This partnership aims to improve access to advanced biomarker testing in community health systems and underserved regions by enabling local testing and supporting targeted therapy development. The initiative builds on strong scientific collaboration and clinical evidence, focusing on health equity and addressing unmet needs in cancer care.
Illumina Says China Removed Ban on Importing DNA Sequencers
Illumina announced that China has removed its ban on importing DNA sequencers, a development that could significantly impact the company's business within the Chinese market. This decision follows complex regulatory and trade discussions, potentially opening new avenues for medical and research advancements in China.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock rise by 2.96% to $126.59 on Thursday, marking its fifth consecutive day of gains. This performance occurred on a generally poor trading day where the S&P 500 Index and Dow Jones Industrial Average both experienced declines. The article highlights Illumina's strong showing despite a broader market downturn.
Illumina Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Illumina Inc.'s stock (ILMN) advanced 1.31% on Tuesday, closing at $120.84, marking its third consecutive day of gains. Despite this positive movement, the stock underperformed compared to the broader market, as the S&P 500 Index rose 0.25% and the Dow Jones Industrial Average increased by 0.10%.
Bamco Inc. NY Sells 39,378 Shares of Illumina, Inc. $ILMN
Bamco Inc. NY sold 39,378 shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, reducing its stake by 15.9% to 208,094 shares valued at approximately $19.76 million. The company recently reported Q3 earnings per share of $1.35 and revenue of $1.16 billion, beating analyst expectations. Despite a consensus "Hold" rating from analysts with an average target price of $129.69, SVP Patricia Leckman also sold 2,370 shares, further decreasing insider holdings.
Illumina, Inc. $ILMN Stake Lessened by Cannell & Spears LLC
Cannell & Spears LLC reduced its stake in Illumina (NASDAQ:ILMN) by 3.7% in Q3, selling 9,119 shares but still holding 239,301 shares valued at approximately $22.73 million. This comes as institutional investors now own 89.42% of the company's stock. Additionally, SVP Patricia Leckman sold 2,370 shares, decreasing her position by 12.68%, while Illumina reported strong Q4 results, exceeding revenue and EPS expectations.
Quinn Opportunity Partners LLC Sells 62,423 Shares of Illumina, Inc. $ILMN
Quinn Opportunity Partners LLC significantly reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by selling 62,423 shares in Q3, now holding 35,264 shares valued at $3.35 million. This follows other institutional investors modifying their positions and an insider sale by SVP Patricia Leckman. Despite the sales, Illumina reported stronger-than-expected Q3 earnings and revenue, providing FY2026 guidance, and analysts currently give the stock a "Hold" rating with a target price of $129.69.
Illumina Inc. stock outperforms competitors despite losses on the day
Illumina Inc. (ILMN) shares fell 1.55% to $122.35 on Tuesday, marking its seventh consecutive day of losses, despite an overall grim trading session for the broader stock market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines. This report highlights Illumina's performance relative to the general market trend.
ARK Investment Management LLC Has $139.41 Million Position in Illumina, Inc. $ILMN
ARK Investment Management LLC increased its stake in Illumina, Inc. by 25.7% in Q3, owning 1,467,879 shares valued at approximately $139.41 million. Illumina recently surpassed quarterly estimates with EPS of $1.35 and revenue of $1.16 billion and provided FY2026 guidance. Analyst ratings are mixed, with a consensus "Hold" and an average price target of $129.69.
Handelsbanken Fonder AB Boosts Stake in Illumina, Inc. $ILMN
Handelsbanken Fonder AB increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 27.7% in the third quarter, acquiring an additional 11,200 shares to bring its total holdings to 51,600 shares valued at $4.9 million. This increase follows Illumina's strong Q3 results, where it surpassed EPS and revenue estimates, and provided robust FY2026 guidance. Despite a consensus "Hold" rating from analysts with an average price target of $129.69, several institutional investors have recently adjusted their positions in the company, and some insiders have sold shares.
Illumina, Inc. (NASDAQ:ILMN) Receives Average Rating of "Hold" from Analysts
Illumina, Inc. (NASDAQ:ILMN) has received an average rating of "Hold" from analysts, with a consensus 1-year price target of $127.94. The company recently surpassed Q4 earnings expectations and set a positive FY2026 guidance. Despite this, there has been recent insider selling, and institutional investors and hedge funds hold a significant majority of the shares.
Pioneering Genomic Progress: An Interview with Rami Mehio, Illumina's Software and Informatics Expert
Rami Mehio, Head of Software and Informatics at Illumina, discusses Illumina's crucial role in the UK Biobank's whole genome sequencing project, highlighting their contributions in sequencing technology and bioinformatics using DRAGEN and ICA cloud platform. He elaborates on the challenges of analyzing 500,000 genomes, such as computational infrastructure and data aggregation, and how Illumina's technology improved variant identification and data compatibility. The interview also touches on the broader implications of these advancements for precision medicine, drug discovery, and the importance of collaboration in genomic research.
Genomics Market Size To Hit USD 157.47 Billion By 2033
The global genomics market is projected to grow significantly from USD 33.90 billion in 2023 to USD 157.47 billion by 2033, driven by increasing demand for novel therapeutic and research applications, technological advancements, and supportive government funding. Key drivers include personalized medicine, falling sequencing costs, and growing applications in understanding and treating genetic disorders and diseases like cancer. Challenges persist in managing and securely storing the vast amounts of generated genomic data.
Shareholders in Illumina (NASDAQ:ILMN) have lost 77%, as stock drops 6.8% this past week
Illumina (NASDAQ:ILMN) shareholders have experienced significant losses, with the stock plunging 78% over the last three years and 42% in the past year. The recent 6.8% drop adds to the concern, raising questions about the company's long-term stock performance despite maintaining top-line revenue and paying dividends. While the company has been profitable in the past, its current trailing twelve-month loss suggests an inconsistent profit record.
Illumina SVP Leckman sells $275k in stock
Patricia Leckman, SVP and Chief People Officer at Illumina, sold 2,370 shares of common stock for $275,346 on February 18, 2026, and an additional 1,304 shares for $151,929 on February 15, 2026. Despite these insider sales, InvestingPro data indicates aggressive share buybacks by management and the company recently surpassed Q4 2025 earnings and revenue expectations. Illumina's stock has seen an 80.18% price return over the past six months and holds a "fair" financial health score.
Illumina Stock is Down 80% From Its All-Time Highs: Can It Recover in 2026?
Illumina stock is down 80% from its all-time highs, but recent Q4 2025 earnings show promise with revenue beat and clinical consumables growth. The company completed the SomaLogic acquisition, adding proteomics, which is expected to contribute to revenue growth despite some EPS dilution and margin compression. A TIKR valuation model projects an 11% annualized return to $158 by December 2028, contingent on sustained clinical consumables momentum and successful integration of SomaLogic.
Illumina To Webcast Upcoming Investor Conference
Illumina, Inc. announced that its management team will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026. A fireside chat is scheduled for 12:10 p.m. PT (3:10 p.m. ET) and a webcast will be available on Illumina's investor relations website, with a replay archived for at least 30 days. Illumina is a global leader in DNA sequencing and array-based technologies, focusing on improving human health through genomics.
Decoding early synaptic failure in Alzheimer’s disease through multiomic analysis
This article announces a webinar titled "Decoding early synaptic failure through multiomics," focusing on Alzheimer's disease. The webinar will delve into a multiomic reanalysis of synaptosome data, integrating mRNA and miRNA data to reveal regulatory signals underlying synaptic dysfunction. It aims to demonstrate practical multiomic workflows using Illumina Connected Multiomics software for Alzheimer's disease research.
Illumina (NASDAQ:ILMN) Upgraded by Wall Street Zen to Strong-Buy Rating
Wall Street Zen has upgraded Illumina (NASDAQ:ILMN) from a "buy" to a "strong-buy" rating, causing its stock to trade up by approximately 2.1%. Despite this upgrade, the overall analyst consensus for Illumina remains a "Hold" with an average price target of $129.17. The company recently reported strong quarterly earnings of $1.35 EPS and revenue of $1.16 billion, exceeding expectations, and has set optimistic guidance for FY2026.
Krilogy Financial LLC Takes $1.34 Million Position in Illumina, Inc. $ILMN
Krilogy Financial LLC has acquired a new position in Illumina, Inc. (NASDAQ:ILMN) during the third quarter, purchasing 14,120 shares valued at approximately $1.34 million. Illumina recently surpassed its quarterly earnings expectations with $1.35 EPS and $1.16 billion in revenue, and has set a FY2026 EPS guidance of $5.050-$5.200. Institutional investors hold a significant 89.42% of the company's stock, though analysts currently maintain a "Hold" rating with an average target price of $129.17.
Illumina, Inc. $ILMN Stock Holdings Lowered by Rhumbline Advisers
Rhumbline Advisers reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 2.1% in the third quarter of 2025, selling 13,289 shares and holding 618,663 shares valued at approximately $58.8 million. Despite this, institutional ownership remains high at 89.42%, with other major firms like WCM Investment Management and AQR Capital Management increasing their positions. Analysts offer a mixed consensus rating of "Hold" with a target price of $129.17, while Illumina recently surpassed EPS and revenue expectations and provided FY2026 guidance.
5 Insightful Analyst Questions From Illumina's Q4 Earnings Call
Illumina reported strong Q4 performance driven by its clinical consumables business, exceeding revenue and adjusted earnings expectations. Despite this, the market reacted negatively due to concerns about sustainability and subdued research demand. This article highlights five insightful analyst questions from the earnings call, focusing on topics like operating margins, growth guidance, competitive dynamics, clinical growth drivers, and China's regulatory environment.
Scott Gottlieb Buys 200 Shares of Illumina (NASDAQ:ILMN) Stock
Illumina director Scott Gottlieb recently purchased 200 shares of the company's stock, increasing his total holdings to 12,723 shares. This insider transaction occurred as Illumina shares saw a slight decline and traded near their 200-day moving average. The company had previously reported better-than-expected earnings and raised its FY2026 guidance, though analysts maintain a mixed "Hold" rating on the stock.
Ngs Oncology Market Is Going to Boom | Illumina • Roche • Thermo Fisher Scientific
A new report by Coherent Market Insights analyzes the global NGS Oncology Market, highlighting its rapid growth driven by rising demand and innovation. The report provides a comprehensive segmentation, competitive analysis of key players like Illumina and Roche, and forecasts substantial growth from 2026 to 2033. It offers insights into market trends, drivers, challenges, and strategic opportunities for industry leaders and investors.
Spatial Genomics and Transcriptomics Market size to cross $956.5 Million by 2035 | 10x Genomics, NanoString Technologies, Illumina, Inc, Thermo Fisher Scientific, Akoya Biosciences
The Spatial Genomics and Transcriptomics Market is projected to reach USD 956.5 million by 2035, growing at a CAGR of 12.5% from its 2025 valuation of USD 331.4 million. This growth is driven by increasing demand for high-resolution molecular profiling in areas like oncology and precision medicine. North America currently dominates the market, with Asia Pacific expected to be the fastest-growing region, while key trends include multi-omics integration and AI-driven data analysis.
This Week in Chancery Court: Trump Media SPAC Appeal, Illumina
This article details the key cases scheduled for Delaware's Chancery Court and Supreme Court this week, including an appeal involving Donald Trump's social media company's SPAC merger, a dispute over a film studio's solvency involving China's Fosun International, and Illumina's legal battle regarding its acquisition of Grail Inc. It highlights the complexities of corporate governance and financial disputes in Delaware courts.
Illumina Crash 10% on Earnings: Why the Stock Could Rebound to $185 in 2026
Illumina (ILMN) shares dropped over 10% despite a "beat and raise" earnings report, driven by investor concerns about the pace of the genomics market recovery and "transition friction" as customers adopt the new NovaSeq X series. Despite the market reaction, TIKR's Advanced Valuation Model suggests the stock is undervalued with a 53.7% upside to a target price of $184, predicting a rebound as the NovaSeq X transition completes by the end of 2026 and margins expand. The company maintains a strong market position, and analysts see the current valuation as a potential overreaction that could reverse.
Illumina, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Illumina, Inc. (NASDAQ:ILMN) saw its stock drop by 17% after its full-year earnings report, despite revenues aligning with analyst predictions. The company surprised with a 14% higher statutory profit per share. Analysts have slightly increased revenue estimates for 2026 but maintained the consensus price target of US$137, indicating a focus on earnings as the primary value driver.
UBS Adjusts Illumina Price Target to $135 From $120, Maintains Neutral Rating
UBS has adjusted its price target for Illumina (ILMN) to $135, up from the previous $120, while maintaining a Neutral rating on the stock. This update reflects a re-evaluation by the investment bank regarding the DNA sequencing and array-based technology company. The article also lists recent news concerning Illumina, including its Q4 2025 earnings call and guidance for fiscal year 2026, as well as an acquisition and strategic agreements.
Illumina, Inc. (NASDAQ:ILMN) Q4 2025 Earnings Call Transcript
Illumina, Inc. reported strong Q4 2025 results, exceeding expectations with 20% growth in clinical consumables revenue ex-China and a return to overall growth for the year. The company's strategic pillars of core sequencing, scaling multiomics, and expanding data/software capabilities are driving momentum, with a positive outlook for 2026 organic revenue growth of 2% to 4% ex-China and an expected EPS of $5.00 to $5.20, despite initial dilution from the Somalogic acquisition. Key drivers include increasing adoption of sequencing-based diagnostic tests and the NovaSeq X instrument, particularly in clinical applications.
Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates
Illumina (ILMN) reported strong Q4 earnings, surpassing the Zacks Consensus Estimate with $1.35 per share and exceeding revenue expectations with $1.16 billion. The company has consistently beaten EPS and revenue estimates over the past four quarters. Despite outperforming the market year-to-date, the stock currently holds a Zacks Rank #3 (Hold) based on a mixed trend in earnings estimate revisions.
Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Illumina (ILMN) reported Q4 2025 revenue of $1.16 billion, a 5% increase year-over-year, and an EPS of $1.35, surpassing analyst estimates. The revenue exceeded the Zacks Consensus Estimate by 0.35%, and the EPS beat the consensus by 7.42%. Key metrics like product revenue and sequencing consumables revenue also outperformed analyst expectations, indicating a strong financial quarter for the company despite a recent stock decline.
Earnings call transcript: Illumina beats Q4 2025 EPS forecast by 10.66%
Illumina Inc. reported strong Q4 2025 results, with EPS of $1.35 and revenue of $1.16 billion, both exceeding forecasts. Despite these positive financials, the stock experienced a slight decline in after-hours trading. The company provided an optimistic outlook for 2026, projecting organic revenue growth and continued strong performance in its clinical sequencing business, alongside strategic advancements in multi-omics and data solutions.
Illumina Inc (NASDAQ:ILMN) Stock Falls Despite Q4 Earnings Beat on Cautious 2026 Outlook
Illumina Inc (NASDAQ:ILMN) reported strong Q4 2025 earnings, surpassing analyst expectations for both revenue and EPS, driven by growth outside China. Despite the beat, the stock fell significantly in after-hours trading due to a cautious 2026 revenue guidance that, while slightly above previous consensus, disappointed investors looking for a more aggressive outlook. The market reaction indicates that investors are weighing the company's Q4 operational strength against its tempered forward-looking prospects.
Illumina shares tumble as flat revenue disappoints investors By Investing.com
Illumina's shares plunged by 8.7% in after-hours trading despite beating fourth-quarter earnings expectations, due to flat annual revenue for 2025. The genetic sequencing company reported $1.35 EPS and $1.16 billion in revenue for Q4, exceeding analyst estimates, but its full-year revenue of $4.34 billion remained unchanged from 2024. For fiscal year 2026, Illumina forecasts revenue growth of 4-6% and adjusted EPS of $5.05-$5.20, significantly above analyst consensus.
Earnings Flash (ILMN) Illumina, Inc. Reports Q4 Revenue $1.16B, vs. FactSet Est of $1.12B
Illumina, Inc. (ILMN) announced its Q4 revenue reached $1.16 billion, surpassing FactSet's estimate of $1.12 billion. The company also reported Q4 adjusted EPS of $1.35, exceeding the FactSet estimate of $1.24 per share. Illumina has provided earnings guidance for the fiscal year 2026.
Multi-Omics Market Set for Explosive Growth to USD 33.25 Billion
The global Multi-Omics Market, valued at USD 3.25 billion in 2024, is projected to reach USD 33.25 billion by 2033, growing at a CAGR of 26.1%, driven by the rising demand for integrated biological data analysis, advancements in precision medicine, and high-throughput sequencing technologies. North America is expected to hold the largest market share at 48.8%, while Asia Pacific shows the fastest growth. Key players include BD, Thermo Fisher Scientific Inc., and Illumina, Inc., with significant market drivers identified in oncology, drug discovery, and chronic disease research, supported by ongoing technological advancements and strategic mergers.
San Diego Zoo’s Frozen Zoo Gets Genomic Boost
Illumina and the San Diego Zoo Wildlife Alliance have announced a sequencing agreement for the Frozen Zoo, a collection of biological samples from threatened and endangered species. Illumina will sequence up to 4,000 samples from 1,300 species to generate data for wildlife medicine, evolutionary biology, and biodiversity preservation research. This collaboration aims to accelerate genomic discovery and maximize the impact of biobanked samples in combating biodiversity loss.
Mediolanum International Funds Ltd Makes New $914,000 Investment in Illumina, Inc. $ILMN
Mediolanum International Funds Ltd has made a new investment of $914,000 in Illumina, Inc. by acquiring 9,944 shares during the third quarter. Other institutional investors have also increased their positions, with institutional ownership now at roughly 89.42%. Despite analysts maintaining a "Hold" consensus rating with a target price of $127.18, the stock is currently trading near $135.43.
